Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the southwest oncology group experience

Journal of Immunotherapy

Volumn 10, Issue 6, 1991, Pages 426-431

  Hersh, Evan M ^a   Metch, Barbara S ^b   Muggia, Franco M ^c   Brown, Thomas D ^d   Whitehead, Robert P ^e   Budd, George T ^f   Rinehart, John J ^g   Crawford, E David ^h   Bonnet, John D ^g   Behrens, Brent C ⁱ  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

Author keywords

Antitumor activity; Metastatic malignancy; Multiple myeloma; Recombinant human tumor necrosis factor alpha; Sarcoma

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; CANCER PATIENT; CHILL; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DRUG EVALUATION; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGE; NEOPLASMS; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0025792319     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199112000-00006     Document Type: Article

References (36)

1. Balkwill FR. Cytokines in cancer therapy. London: Oxford University Press, 1989: 288.
2. Quesada RJ, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant α-interferon. Blood 1986; 68: 493-7.
3. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990; 82: 1397-402.
4. Golumb HM, Gutterman J, Fefer A, et al. The biological therapy of cancer: a clinical symposium. In: Przepiorka D, Rosenthal SN, Bitran JD, eds. Seminars in Oncology, vol 15. Philadelphia: Grune & Stratton, 1988: 1-54.
5. Mertelsmann R, Gamm H, Flener R, Herrmann F. Recombinant human tumor necrosis factor alpha (rhTNF-alpha) in advanced cancer: A phase I clinical trial [Abstract]. Proc Am Assoc Cancer Res 1987; 28: 399.
6. Oettgen HF, Carswell EA, Kassel RL, et al. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res 1980; 75: 207-12.
7. Beutler B, Milsark 1W, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
8. Lowry SF, Moldawer LL. Tumor necrosis factor and other cytokines in the pathogenesis of cancer cachexia. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. Philadelphia: J. B. Lippincott Co., 1990: 1-12.
9. Scuderi P, Lam KS, Ryan KJ, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986; 2: 1364-5.
10. Girardin E, Grau GE, Dayer JM, et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N EnglJ Med 1988; 319: 397-400.
11. Philip R, Epstein LB. Tumour necrosis factor as immuno-modulator and mediator of monocyte cytotoxicity induce by itself, γ-interferon, and interleukin-1. Nature 1986; 323: 86-9.
12. +, LAK cell clones to produce interferon-γ and tumor necrosis factor upon stimulation with tumor targets. Cancer Immunol Im-munother 1989; 29: 270-8.
13. Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 1987; 138: 2711-7.
14. Regenass U, Muller M, Curschellas E, Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 1987; 39: 266-73.
15. 1. J Immunol 1989; 142: 2133-9.
16. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoi-somerase II. Cancer Res 1987; 47: 2403-6.
17. Feinberg B, Kurzrock R, Blick M, Talpaz M, Saks S, Gutterman J. Phase I study of recombinant tumor necrosis factor in patients with disseminated cancer [Abstract]. Proc Am Soc Clin Oncol 1987; 6: 238.
18. Gabrilove JL, Starnes HF, Begas A, et al. A phase I study of intravenously administered rTNF-alpha in patients with advanced cancer [Abstract]. Proc Am Soc Clin Oncol 1987; 6: 247.
19. Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20: 223-9.
20. Manda T, Shimomura K, Mukumoto S, et al. Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res 1987; 47: 3707-11.
21. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951-4.
22. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228: 149-54.
23. Sugarman BJ, Aggarwal BB, Hass PE, Figari IA, Palladino Jr MA, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-5.
24. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxin interaction with human interferon. Proc Natl Acad Sci USA 1983; 80: 5397-401.
25. Krigel R, Comis R, Padavic K, Konrad M, Bradley E, Rudolph A. Phase I trials of recombinant tumor necrosis factor (rTNF) in patients with advanced malignancy [Abstract]. Proc Am Soc Clin Oncol 1987; 6: 241.
26. Jakubowski AA, Casper ES, Gabrilove JL, et al. Phase I trial of intramuscularly (IM) administered tumor necrosis factor (TNF) in adults with advanced cancer [Abstract]. Proc Am Soc Clin Oncol 1987; 6: 243.
27. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-9.
28. Trump DL, Remick SC, Alberti D, et al. A clinical trial of recombinant tumor necrosis factor (rTNF) administered three times weekly [Abstract]. Proc Am Soc Clin Oncol 1987; 7: 168.
29. Taylor C, Hersh E, Plezia P, et al. A phase I and pharma-cokinetic study of recombinant tumor necrosis factor (rTNF) and doxorubicin (DOX) [Abstract]. Proc Am Soc Clin Oncol 1989; 8: 183.
30. Schwartzberg L, Tauer K, Birch R, et al. Phase I study of sequential recombinant tumor necrosis factor (rTNF) and recombinant interleukin-2 (rIL-2) in patients with advanced malignancy [Abstract]. Proc Am Soc Clin Oncol 1989; 8: 183.
31. Salmon SE, Young L, Scuderi P, Clark B. Antineoplastic effects of tumor necrosis factor alone and in combination with gammα-interferon on tumor biopsies in clonogenic assay. J Clin Oncol 1987; 5: 1816-21.
32. Eisenhauer E, Wierzbicki R, Venner P, Skillings J, Letendre F. Phase II trial of recombinant tumor necrosis factor (rTNF) in patients with renal cell carcinoma (RCC) [Abstract]. Proc Am Soc Clin Oncol 1990; 9: 139.
33. Otto U, Conrad S, Schneider AW, Kempeni J, Schlick E, Klosterhalfen H. Combined therapy with TNF-alpha and INF-alpha-2a: a promising approach to treatment of metastatic renal cell carcinoma [Abstract]. Proc Am Soc Clin Oncol 1990; 9: 147.
34. Figlin R, deKernion J, Sarna G, Moldawer N, Saks S. Phase II study of recombinant tumor necrosis factor (rTNF) in patients with metastatic renal cell carcinoma (RCCa) and malignant melanoma (MM) [Abstract]. Proc Am Soc Clin Oncol 1988; 7: 169.
35. Mavligit G, Zukwiski A, Wallace S, Kempeni J, Schlick E, Kaufmann M. Tumor regression after hepatic arterial infusion of recombinant tumor necrosis factor in patients with colon carcinoma metastatic to the liver [Abstract], Proc Am Soc Clin Oncol 1990; 9: 118.
36. Raeth U, Schmid H, Karck U, Kempeni J, Schlike E, Kaufmann M. Phase-II trial of recombinant human tumor necrosis factor α (rHuTNF) in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread [Abstract]. Proc Am Soc Clin Oncol 1990; 10: 187.